NO982036L - Forbindelse egnet for behandling av traumatisk hjerneskade - Google Patents

Forbindelse egnet for behandling av traumatisk hjerneskade

Info

Publication number
NO982036L
NO982036L NO982036A NO982036A NO982036L NO 982036 L NO982036 L NO 982036L NO 982036 A NO982036 A NO 982036A NO 982036 A NO982036 A NO 982036A NO 982036 L NO982036 L NO 982036L
Authority
NO
Norway
Prior art keywords
traumatic brain
brain injury
treatment
compound suitable
injury
Prior art date
Application number
NO982036A
Other languages
English (en)
Norwegian (no)
Other versions
NO982036D0 (no
Inventor
Brian R Pike
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO982036D0 publication Critical patent/NO982036D0/no
Publication of NO982036L publication Critical patent/NO982036L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO982036A 1995-11-06 1998-05-05 Forbindelse egnet for behandling av traumatisk hjerneskade NO982036L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK123295 1995-11-06
PCT/DK1996/000458 WO1997017074A1 (en) 1995-11-06 1996-11-05 Treatment of traumatic brain injury

Publications (2)

Publication Number Publication Date
NO982036D0 NO982036D0 (no) 1998-05-05
NO982036L true NO982036L (no) 1998-06-25

Family

ID=8102484

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982036A NO982036L (no) 1995-11-06 1998-05-05 Forbindelse egnet for behandling av traumatisk hjerneskade

Country Status (18)

Country Link
EP (1) EP0866706A1 (is)
JP (1) JPH11514654A (is)
KR (1) KR19990067353A (is)
AU (1) AU706594B2 (is)
BG (1) BG63150B1 (is)
BR (1) BR9611396A (is)
CA (1) CA2234824A1 (is)
CZ (1) CZ287441B6 (is)
EA (1) EA000531B1 (is)
HU (1) HUP9901051A2 (is)
IS (1) IS4726A (is)
NO (1) NO982036L (is)
NZ (1) NZ321546A (is)
PL (1) PL326490A1 (is)
SK (1) SK58198A3 (is)
TR (1) TR199800801T2 (is)
WO (1) WO1997017074A1 (is)
ZA (1) ZA969320B (is)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013096A1 (es) * 1997-07-01 2000-12-13 Lundbeck & Co As H Sal de adicion de acido maleico de 5-(2-etil-2-h-tetrazol-5-il)-1-metil- 1,2,3,6-tetrahidropiridina, composicion farmaceutica que la contiene, su usoen terapia y metodo de preparacion de la misma.
RU2266737C1 (ru) * 2004-04-12 2005-12-27 Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Россиской Академии Наук Препарат для лечения геморрагического инсульта и способ лечения геморрагического инсульта
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
US5328925A (en) * 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
IE922270A1 (en) * 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
US5330994A (en) * 1992-03-24 1994-07-19 Warner-Lambert Company Tetrahydropyridine isoxazoline derivatives

Also Published As

Publication number Publication date
EP0866706A1 (en) 1998-09-30
NZ321546A (en) 2000-12-22
SK58198A3 (en) 1998-10-07
TR199800801T2 (xx) 1998-08-21
AU706594B2 (en) 1999-06-17
ZA969320B (en) 1997-05-30
CZ287441B6 (en) 2000-11-15
AU7490096A (en) 1997-05-29
EA000531B1 (ru) 1999-10-28
BR9611396A (pt) 1999-07-13
MX9803432A (es) 1998-09-30
KR19990067353A (ko) 1999-08-16
WO1997017074A1 (en) 1997-05-15
CA2234824A1 (en) 1997-05-15
BG102480A (en) 1999-01-29
IS4726A (is) 1998-04-27
HUP9901051A2 (hu) 2000-03-28
JPH11514654A (ja) 1999-12-14
EA199800434A1 (ru) 1998-10-29
NO982036D0 (no) 1998-05-05
CZ138998A3 (cs) 1998-10-14
BG63150B1 (bg) 2001-05-31
PL326490A1 (en) 1998-09-28

Similar Documents

Publication Publication Date Title
NO974378D0 (no) Fremgangsmåte til behandling av gasser
ATE237303T1 (de) Verwendung von zusammensetzungen mit benzoylperoxyd, glycolsäure und zink zur behandlung von dermatologischen krankheiten
NO924461D0 (no) Dipyridamol for behandling av proliferaktive sykdommer
DE69620306D1 (de) 4-(.Alpha.-hydroxy-.alpha.-aryl-alkylcarbonylamino)-Piperidine zur Behandlung und Prophylaxe von Erkrankungen der Harnwege
AU6452194A (en) Pharmaceutical agents for treatment of emesis
NO953443D0 (no) Fremgangsmåte for behandling av fast avfall
NO881322D0 (no) Fremgangsmaate og anlegg for behandling av returnert boreslam.
NO982036L (no) Forbindelse egnet for behandling av traumatisk hjerneskade
NO953254D0 (no) Substituerte azolonderivater for behandling av sykdommer forårsaket av helikobakter
WO1997003188A3 (de) Verwendung von mp52 oder mp121 zur behandlung und prävention von erkrankungen des nervensystems
DE69824576D1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
DE69825605D1 (de) Behandlung der schizophrenie und der psychose
DE69613597D1 (de) Verfahren zur Herstellung von Cyclopentadienyl-Verbindungen und nach dem Verfahren hergestellte Verbindungen
NO993627L (no) Anvendelse av en forbindelse for fremstilling av et legemiddel
NO961226L (no) Blandinger for forebyggelse og behandling av viralinduserte tumorer
NO890643L (no) Fremgangsmaate ved behandling av avluft og avgass.
NO982582L (no) Fremgangsmaate for behandling av smerte
NO885287D0 (no) Fremgangsmÿte ved behandling av boreslam.
NO962259L (no) Anvendelse av dimeticon for behandling av aphthae og stomatitt
DE69738320D1 (de) Verwendung von pyrolidin-derivaten zur herstellung von arzneimitteln zur behandlung von drogenmissbrauch
NO982562D0 (no) Sammensetning for behandling av smerte
DE69632677D1 (de) Verwendung eines Rifamycin-Derivates zur Herstellung eines Medikamentes zur Behandlung von Krankheiten verursacht durch Helicobacter pylori-Infektionen
NO893710D0 (no) Fremgangsmaate for behandling av bark for havebruk.
DE69327074D1 (de) Substituierte 1,2,4-Triazine-3,5-Dion Derivate und diese enthaltende Arzneimittel, insbesondere zur Behandlung von Coccidiose
DE69632117D1 (de) Verwendung von 8,9-Dehydroestron zur Herstellung eines Arzneimittels zur Behandlung von durch freie Radikale verursachte Krankheiten

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application